{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T17:40:21Z","timestamp":1730828421684,"version":"3.28.0"},"reference-count":52,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background The objective of this study was to compare the safety profiles\n                    of OCA and UDCA for the treatment of PBC using the FDA Adverse Event Reporting\n                    System database.<\/jats:p><jats:p>\n          Methods We extracted reports for OCA from 2016 to 2023 and UDCA from 2004\n                    to 2023. Demographic details, adverse events (AEs), and concomitant medications\n                    were analyzed using descriptive statistics and signal detection methods.<\/jats:p><jats:p>\n          Results The most common for OCA were pruritus (1345 cases, ROR 20.96) and\n                    fatigue (528 cases, ROR 3.46). UDCA was more frequently associated with\n                    hepatocellular carcinoma (22 cases, ROR 16.37) and type I hypersensitivity\n                    reactions (11 cases, ROR 12.77). OCA was also linked to a higher frequency of\n                    constipation (161 cases, ROR 3.92) and increased blood alkaline phosphatase\n                    levels (145 cases, ROR 44.27).<\/jats:p><jats:p>\n          Conclusion This study reveals distinct safety profiles for OCA and UDCA in\n                    the treatment of PBC. OCA is associated with a higher frequency of pruritus,\n                    fatigue, constipation, and increased blood alkaline phosphatase levels, while\n                    UDCA is linked to hepatocellular carcinoma and type I hypersensitivity\n                    reactions. These findings support personalized treatment approaches based on\n                    individual patient characteristics.<\/jats:p>","DOI":"10.1055\/a-2401-4700","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T23:21:43Z","timestamp":1727133703000},"page":"464-474","source":"Crossref","is-referenced-by-count":0,"title":["A Comparative Analysis of ADRs under Obeticholic Acid and\n                    Ursodeoxycholic Acid in Cholestatic Liver Diseases Using the FAERS\n                    Database"],"prefix":"10.1055","volume":"74","author":[{"given":"Meng","family":"Zhu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Zhejiang Chinese Medical University,\n                    Binjiang District, Hangzhou, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linghui","family":"Tao","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Zhejiang Chinese Medical University,\n                    Binjiang District, Hangzhou, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiye","family":"Zhu","sequence":"additional","affiliation":[{"name":"Academy of Chinese Medical Sciences, Zhejiang Chinese Medical\n                    University, Binjiang District, Hangzhou, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Zhejiang Chinese Medical University,\n                    Binjiang District, Hangzhou, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7861\/clinmed.2020-0697","article-title":"An update on the management of cholestatic liver diseases","volume":"20","author":"G Appanna","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.14218\/JCTH.2022.00147","article-title":"Guidelines for the Management of Cholestatic Liver Diseases (2021)","volume":"10","author":"L Lu","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1053\/jhep.2001.25086","article-title":"Alterations in tight junctions differ between primary biliary cirrhosis and\n                    primary sclerosing cholangitis","volume":"33","author":"S Sakisaka","year":"2001","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mam.2013.10.001","article-title":"Chronic cholestatic liver diseases: clues from histopathology for\n                    pathogenesis","volume":"37","author":"M J Pollheimer","year":"2014","journal-title":"Mol Aspects Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.3748\/wjg.v28.i39.5764","article-title":"Serum metabolic profiling of targeted bile acids reveals potentially novel\n                    biomarkers for primary biliary cholangitis and autoimmune hepatitis","volume":"28","author":"Z H Ma","year":"2022","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042194","article-title":"Current Perspectives on the Molecular and Clinical Relationships between Primary\n                    Biliary Cholangitis and Hepatocellular Carcinoma","author":"A Floreani","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12967-024-05029-6","article-title":"Multi-omics approaches for drug-response characterization in primary biliary\n                    cholangitis and autoimmune hepatitis variant syndrome","volume":"22","author":"F Yang","year":"2024","journal-title":"J Transl Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"101105","DOI":"10.1016\/j.aohep.2023.101105","article-title":"Risk factors for cancer in patients with primary biliary cholangitis and\n                    autoimmune hepatitis and primary biliary cholangitis overlap syndrome","volume":"28","author":"M H Braga","year":"2023","journal-title":"Ann Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1055953","DOI":"10.3389\/fimmu.2022.1055953","article-title":"Low vitamin D concentrations and BMI are causal factors for primary biliary\n                    cholangitis: A mendelian randomization study","volume":"13","author":"H Xu","year":"2022","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12016-015-8502-y","article-title":"Epigenetics and Primary Biliary Cirrhosis: a Comprehensive Review and\n                    Implications for Autoimmunity","volume":"50","author":"Y Q Xie","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"103163","DOI":"10.1016\/j.jaut.2023.103163","article-title":"Immunosuppression induces regression of fibrosis in primary biliary cholangitis\n                    with moderate-to-severe interface hepatitis","volume":"143","author":"R Wang","year":"2024","journal-title":"J Autoimmun"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.clinre.2020.03.026","article-title":"Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone\n                    and immunosuppressants in patients not responding to ursodeoxycholic acid alone\n                    and the prognostic indicators","volume":"44","author":"J D Qian","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary\n                    cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","volume":"78","author":"G M Hirschfield","year":"2023","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cgh.2022.07.024","article-title":"Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist\n                    Cilofexor Over a 96-Week Open-label Extension in Patients With PSC","volume":"21","author":"M Trauner","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/nu15030760","article-title":"Selected Aspects of the Intricate Background of Immune-Related\n                    Cholangiopathies-A Critical Overview","author":"B Kasztelan-Szczerbinska","year":"2023","journal-title":"Nutrients"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.01.030","article-title":"Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid","author":"M C van Hooff","year":"2024","journal-title":"Eur J Intern Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1080\/14656566.2016.1218471","article-title":"Obeticholic acid for the treatment of primary biliary cholangitis","volume":"17","author":"A H Ali","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1184252","DOI":"10.3389\/fimmu.2023.1184252","article-title":"Mechanism-based target therapy in primary biliary cholangitis: opportunities\n                    before liver cirrhosis?","volume":"14","author":"Y Yang","year":"2023","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/liv.15816","article-title":"Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects\n                    with fibrosis or cirrhosis from NASH","volume":"44","author":"N Alkhouri","year":"2024","journal-title":"Liver Int"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of\n                    obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic\n                    steatohepatitis","volume":"79","author":"A J Sanyal","year":"2023","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"964399","DOI":"10.3389\/fphar.2022.964399","article-title":"Analysis of pharmacovigilance databases for spontaneous reports of adverse drug\n                    reactions related to substandard and falsified medical products: A descriptive\n                    study","volume":"13","author":"K Pozsgai","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","article-title":"Defining \u02bcsignal\u02bc and its subtypes in pharmacovigilance based on a systematic\n                    review of previous definitions","volume":"32","author":"M Hauben","year":"2009","journal-title":"Drug Saf"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/cpt.2172","article-title":"A New Era in Pharmacovigilance: Toward Real-World Data and Digital\n                    Monitoring","volume":"109","author":"A Lavertu","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"E G Brown","year":"1999","journal-title":"Drug Saf"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S1470-2045(16)30312-6","article-title":"21st century pharmacovigilance: efforts, roles, and responsibilities","volume":"17","author":"P J Pitts","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"A Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in\n                    spontaneous reporting systems for adverse drug reactions","volume":"11","author":"E P van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"I R Edwards","year":"2000","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(00)02781-1","article-title":"Adverse drug reactions","volume":"356","author":"D Frankel","year":"2000","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"122355","DOI":"10.1016\/j.lfs.2023.122355","article-title":"Obeticholic acid protects against lithocholic acid-induced exogenous cell\n                    apoptosis during cholestatic liver injury","volume":"337","author":"Q Lu","year":"2024","journal-title":"Life Sci"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"115777","DOI":"10.1016\/j.biopha.2023.115777","article-title":"Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting\n                    of the FXR signaling pathway and ECM remodeling","volume":"168","author":"A Azizsoltani","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/liv.15767","article-title":"FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and\n                    inflammation in diet-induced ob\/ob mouse model of NASH","volume":"44","author":"L G Di Pasqua","year":"2024","journal-title":"Liver Int"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"155124","DOI":"10.1016\/j.phymed.2023.155124","article-title":"Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile\n                    acid-NF-\u03baB\/NRF2 axis to reduce bile acid accumulation and its subsequent\n                    inflammation and oxidative stress","volume":"122","author":"M Q Wang","year":"2024","journal-title":"Phytomedicine"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e0005","DOI":"10.1097\/HC9.0000000000000005","article-title":"Safety and tolerability of obeticholic acid in chronic liver disease: a pooled\n                    analysis of 1878 individuals","volume":"7","author":"C H Ng","year":"2023","journal-title":"Hepatol Commun"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"835991","DOI":"10.3389\/fphar.2022.835991","article-title":"Efficacy and safety of pharmacological interventions for pruritus in primary\n                    biliary cholangitis: A systematic review and meta-analysis","volume":"13","author":"C Xu","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.14492","article-title":"Clinical and metabolic effects associated with weight changes and obeticholic\n                    acid in non-alcoholic steatohepatitis","volume":"47","author":"B Hameed","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and\n                    inadequate response to ursodeoxycholic acid","volume":"148","author":"G M Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2019.04.005","article-title":"Therapeutic trials of biologics in primary biliary cholangitis: An open label\n                    study of abatacept and review of the literature","volume":"101","author":"C L Bowlus","year":"2019","journal-title":"J Autoimmun"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.dld.2022.12.010","article-title":"Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A\n                    systematic review and meta-analysis","volume":"55","author":"J Gazda","year":"2023","journal-title":"Dig Liver Dis"},{"volume-title":"Ursodeoxycholic Acid, StatPearls, StatPearls Publishing. Copyright \u00a9 2024","year":"2024","author":"TG O Achufusi","key":"ref43"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s11695-023-06581-8","article-title":"Ursodeoxycholic Acid Use After Bariatric Surgery: Effects on Metabolic and\n                    Inflammatory Blood Markers","volume":"33","author":"MS S Guman","year":"2023","journal-title":"Obes Surg"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000826","article-title":"Predictive factors for decompensating events in cirrhotic\n                    patients with primary biliary cholangitis under different lines of\n                    therapy","author":"J Ampuero","year":"2024","journal-title":"Hepatology"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000864","article-title":"Primary biliary cholangitis drug evaluation and regulatory\n                    approval: Where do we go from\n                    here?","author":"D E Jones","year":"2024","journal-title":"Hepatology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4254\/wjh.v6.i8.601","article-title":"Assessing liver injury associated with antimycotics: Concise literature review\n                    and clues from data mining of the FAERS database","volume":"6","author":"E Raschi","year":"2014","journal-title":"World J Hepatol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e37271","DOI":"10.1097\/MD.0000000000037271","article-title":"The effect and safety of obeticholic acid for patients with nonalcoholic\n                    steatohepatitis: A systematic review and meta-analysis of randomized controlled\n                    trials","volume":"103","author":"J Zhao","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: Lessons and perspectives from obeticholic\n                    acid","volume":"44","author":"K Wang","year":"2024","journal-title":"Med Res Rev"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"102227","DOI":"10.1016\/j.clinre.2023.102227","article-title":"Effect on lipid profile and clinical outcomes of obeticholic acid for the\n                    treatment of primary biliary cholangitis and metabolic dysfunction-associated\n                    steatohepatitis: A systematic review and meta-analysis","volume":"47","author":"H Jang","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/jat.4410","article-title":"Obeticholic acid improved triptolide\/lipopolysaccharide-induced hepatotoxicity\n                    by inhibiting caspase-11-GSDMD pyroptosis pathway","volume":"43","author":"P Liang","year":"2023","journal-title":"J Appl Toxicol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cgh.2022.07.038","article-title":"UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary\n                    Cholangitis","volume":"21","author":"N Abbas","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of\n                    prospective studies","volume":"279","author":"J Lazarou","year":"1998","journal-title":"Jama"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal\n                    generation","volume":"54","author":"A Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2401-4700.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:58:42Z","timestamp":1730825922000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2401-4700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":52,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2024,10,29]]},"published-print":{"date-parts":[[2024,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2401-4700","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"type":"print","value":"2194-9379"},{"type":"electronic","value":"2194-9387"}],"subject":[],"published":{"date-parts":[[2024,9,23]]}}}